alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Order entered October 2, 2015

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-15-00862-CR

DAVID SHAWN FOTHERGILL, Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the 15th Judicial District Court

Grayson County, Texas

Trial Court Cause No. 063259

ORDER

The Court REINSTATES the appeal.

On September 30, 2015, we ordered the trial court to make findings regarding why 

appellant’s brief had not been filed. On October 1, 2015, we received appellant’s brief, together 

with an extension motion. Therefore, findings are no longer necessary and we VACATE our 

September 30, 2015 order.

We GRANT the October 1, 2015 extension motion and ORDER appellant’s brief filed 

as of the date of this order. 

/s/ ADA BROWN 

JUSTICE
I 

118TH CONGRESS 

2D SESSION H. R. 7299 

To authorize to be appropriated to the Secretary of Housing and Urban 

Affairs, $1,500,000,000 to carry out the HOME Investment Partnership 

Program, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 7, 2024 

Mr. SCHIFF (for himself, Ms. NORTON, Mrs. WATSON COLEMAN, and Mr. 

GOMEZ) introduced the following bill; which was referred to the Committee on Financial Services 

A BILL 

To authorize to be appropriated to the Secretary of Housing 

and Urban Affairs, $1,500,000,000 to carry out the 

HOME Investment Partnership Program, and for other 

purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. AUTHORIZATION OF APPROPRIATIONS. 

4 Subtitle A of title II of Cranston-Gonzales National 

5 Affordable Housing Act (42 U.S.C. 12741 et seq.) is 

6 amended by adding at the end the following: 


lotter on DSK11XQN23PROD with BILLS
2 

•HR 7299 IH

1 ‘‘SEC. 227. AUTHORIZATION OF APPROPRIATIONS. 

2 ‘‘(a) IN GENERAL.—There is authorized to be appro3 priated, to the Secretary of Housing and Urban Affairs, 

4 $1,500,000,000, in each of fiscal years 2024, 2025, 2026, 

5 2027, and 2028, to carry out this subtitle. 

6 ‘‘(b) ADDITIONAL AMOUNT.—In addition the amount 

7 authorized to be appropriated pursuant to subsection (a), 

8 there is authorized to be appropriated $500,000,000, in 

9 each of fiscal years 2024, 2025, 2026, 2027, and 2028, 

10 for projects conducted under this subtitle that build or re11 habilitate childcare facilities.’’. 

Æ 


lotter on DSK11XQN23PROD with BILLS
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5580 Oxygen mask. ( a ) *Identification.* An oxygen mask is a device placed over a patient's nose, mouth, or tracheostomy to administer oxygen or aerosols.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38795, July 25, 2001]
#### § 1108.65 Award administration office.

*Award administration office* means a DoD Component office that performs post-award functions related to the administration of grants, cooperative agreements, technology investment agreements, or other nonprocurement instruments subject to one or more parts of the DoDGARs.
**Exhibit31.1**

**CERTIFICATION**

I, Robin Raina, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ebix, Inc.;

2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant’s disclosure controlsand procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the registrant’s fourth fiscal quarter in the case of anannual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting;and

5. The registrant’s other certifying officer and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of theregistrant’s board of directors (or persons performing the equivalentfunctions):

(a) All significant deficiencies and material weaknesses in the designor operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant’s ability to record, process,summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management orother employees who have a significant role in the registrant’s internalcontrol over financial reporting.

 
| Date:  November 20, 2006 |   | /s/ Robin Raina          |   |   |
|------------------------------------|--------|--------------------------|--------|--------|
|                               |   | Robin Raina              |   |   |
|                               |   | Chief Executive  Officer |   |   |

 

----
<PAGE>

                                                                    Exhibit 99.1

                            CERTIFICATION PURSUANT TO
                            18 U. S. C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report of Ecogen, Inc. (the "Company") on Form
10-Q for the period ended July 31, 2002 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, James P. Reilly, Jr.,
as Chief Executive Officer and Acting Chief Financial Officer of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:

     (1)  The Report fully complies with the requirements of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934: and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operations
          of the Company.

                                               /s/ James P. Reilly, Jr.
                                               ------------------------
                                               James P. Reilly, Jr.
                                               Chief Executive Officer and
                                               Acting Chief Financial Officer

                                               September 26, 2002
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-END>                               JUN-29-1997
<CASH>                                          27,780
<SECURITIES>                                         0
<RECEIVABLES>                                  575,821
<ALLOWANCES>                                    38,851
<INVENTORY>                                    562,718
<CURRENT-ASSETS>                             1,174,650
<PP&E>                                         796,973
<DEPRECIATION>                                 290,087
<TOTAL-ASSETS>                               2,380,598
<CURRENT-LIABILITIES>                          523,620
<BONDS>                                      1,271,251
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           213
<OTHER-SE>                                     331,751
<TOTAL-LIABILITY-AND-EQUITY>                 2,380,598
<SALES>                                        490,365
<TOTAL-REVENUES>                               490,365
<CGS>                                          366,057
<TOTAL-COSTS>                                  366,057
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                 1,701
<INTEREST-EXPENSE>                              29,264
<INCOME-PRETAX>                               (11,295)
<INCOME-TAX>                                   (3,559)
<INCOME-CONTINUING>                            (7,445)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  7,313
<CHANGES>                                            0
<NET-INCOME>                                  (14,758)
<EPS-PRIMARY>                                   (0.69)
<EPS-DILUTED>                                   (0.69)
        

</TABLE>
<PAGE>


                                                                    EXHIBIT 23.1


                        CONSENT OF INDEPENDENT AUDITORS


We consent to the incorporation by reference in the Registration Statement (Form
S-8) filed with the Securities and Exchange Commission on December 10, 1999
pertaining to the 1995 Israel Stock Option Plan, 1997 Stock Option Plan and 1998
Non-Employee Director Share Option Plan of Nur Macroprinters, of our report
dated February 14, 2002, with respect to the consolidated financial
statements of Nur Macroprinters included in this Annual Report (Form 20-F) for
the year ended December 31, 2001.

Tel-Aviv, Israel
June 21, 2002

                                         Yours truly,

                                         /s/ Kost Forer & Gabbay

                                         KOST FORER & GABAY

                                         A member of Ernst & Young International
# C_2015311EN.01004701.xml

| 21.9.2015 | EN | Official Journal of the European Union | C 311/47 |
| --- | --- | --- | --- |

21.9.2015

EN

Official Journal of the European Union

C 311/47

---

Order of the General Court of 24 June 2015 — Wm. Wrigley Jr. v OHIM (Representation of a sphere)

(Case T-625/14) (1)

1

((Community trade mark - Application for Community figurative mark representing a sphere - Absolute grounds for refusal - No distinctive character - Article 7(1)(b) of Regulation (EC) No 207/2009 - Action manifestly lacking any foundation in law))

(2015/C 311/51)

Language of the case: English

Parties

Parties

Applicant: Wm. Wrigley Jr. Company (Wilmington, Delaware, United States) (represented by: M. Kinkeldey, S. Brandstätter and C. Schmitt, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: J. Crespo Carillo, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Fifth Board of Appeal of OHIM of 17 June 2014 (Case R 168/2014-5) relating to an application for registration of a figurative sign representing a sphere as a Community trade mark.

Operative part of the order

Operative part of the order

| 1. | The action is dismissed. |
| --- | --- |

1.

The action is dismissed.

| 2. | Wm. Wrigley Jr. Company shall pay the costs. |
| --- | --- |

2.

Wm. Wrigley Jr. Company shall pay the costs.

---

(1)  OJ C 351, 6.10.2014.

1

---
<PAGE>   1
                                                                    EXHIBIT 23.4


              CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

We consent to the incorporation by reference in the Registration Statement (Form
S-8), pertaining to the Anergen, Inc. 1988 Stock Option Plan, the Anergen, Inc.
1992 Consultant Plan, the Anergen, Inc. 1995 Director Plan and the Anergen, Inc.
1996 Stock Option Plan, of Corixa Corporation of our report dated January 28,
1998 except for Note 9, as to which the date is February 28, 1998 with respect
to the financial statements of GenQuest Inc. included in Current Report on Form
8-K of Corixa Corporation dated August 9, 1999 filed with the Securities and
Exchange Commission.

                                                               ERNST & YOUNG LLP

Seattle, Washington
October 21, 1999
<TABLE> <S> <C>

<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                9-MOS
<FISCAL-YEAR-END>                    DEC-31-1999
<PERIOD-END>                         SEP-30-1999
<CASH>                                      476
<SECURITIES>                                  0
<RECEIVABLES>                          2,431,533
<ALLOWANCES>                             56,549
<INVENTORY>                            2,190,219
<CURRENT-ASSETS>                       5,881,780
<PP&E>                                 9,607,135
<DEPRECIATION>                         7,374,870
<TOTAL-ASSETS>                        8,302,199
<CURRENT-LIABILITIES>                 3,391,400
<BONDS>                               6,963,754
<PREFERRED-MANDATORY>                         0
<PREFERRED>                                   0
<COMMON>                                     414
<OTHER-SE>                           (9,058,011)
<TOTAL-LIABILITY-AND-EQUITY>          8,302,199
<SALES>                              10,479,797
<TOTAL-REVENUES>                     10,479,797
<CGS>                                 9,747,191
<TOTAL-COSTS>                          9,747,191
<OTHER-EXPENSES>                      1,561,969
<LOSS-PROVISION>                              0
<INTEREST-EXPENSE>                       407,833
<INCOME-PRETAX>                      (1,268,053)
<INCOME-TAX>                                  0
<INCOME-CONTINUING>                  (1,268,053)
<DISCONTINUED>                                0
<EXTRAORDINARY>                               0
<CHANGES>                                     0
<NET-INCOME>                         (1,268,053)
<EPS-BASIC>                             (0.03)
<EPS-DILUTED>                             (0.03)


</TABLE>
CERTIFICATION OF CHIEF EXECUTIVE OFFICER REGARDING
PERIODIC REPORT FILED PURSUANT TO SECTION 13(A) OR 15 (D)
OF THE SECURITIES EXCHANGE ACT OF 1934

I, J.D. Nichols, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

To the best of my knowledge and belief, the Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on August 14, 2002 by NTS-Properties VII, Ltd. and to which this certification
is appended (the "Periodic Report") fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, and the information contained in the Periodic Report fairly
presents, in all material respects, the financial condition and results of operations of NTS-Properties
VII, Ltd..

|                                                
|------------------------------------------------
|                                                
|/s/ J.D. Nichols                                
|                                                
|J.D. Nichols                                    
|General Partner of NTS-Properties Associates VII
|and Chairman of the Board and Sole Director     
|of NTS Capital Corporation                      
|                                                
|
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5810 Airway connector. ( a ) *Identification.* An airway connector is a device intended to connect a breathing gas source to a tracheal tube, tracheostomy tube, or mask.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38795, July 25, 2001]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5900 Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection system. ( a ) *Identification.* The CFTR gene mutation detection system is a device used to simultaneously detect and identify a panel of mutations and variants in the CFTR gene. It is intended as an aid in confirmatory diagnostic testing of individuals with suspected cystic fibrosis (CF), carrier identification, and newborn screening. This device is not intended for stand-alone diagnostic purposes, prenatal diagnostic, pre-implantation, or population screening.
( b ) *Classification.* Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: CFTR Gene Mutation Detection System.” See § 866.1(e) for the availability of this guidance document.
[70 FR 61738, Oct. 26, 2005]
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

RICKY LAND,

Petitioner

v.

PIKE COUNTY DISTRICT AT T ORNEY'S

OFFICE,

Respondent :

:

:

:

:

:

:

:

:

:

:

: No. 96 MM 2023

ORDER

PER CURIAM

AND NOW , this 17 th day of November

, 2023, the Application for Leave to File

Original Process is GRANTED, and the Petition for Writ of Mandamus is DISMISSED.
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.4400 Enzyme preparations. ( a ) *Identification.* Enzyme preparations are products that are used in the histopathology laboratory for the following purposes: ( 1 ) To disaggregate tissues and cells already in established cultures for preparation into subsequent cultures (e.g., trypsin);
( 2 ) To disaggregate fluid specimens for cytological examination (e.g., papain for gastric lavage or trypsin for sputum liquefaction);
( 3 ) To aid in the selective staining of tissue specimens (e.g., diastase for glycogen determination).
( b ) *Classification.* Class I (general controls). This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60592, Sept. 12, 1980, as amended at 54 FR 25045, June 12, 1989; 66 FR 38789, July 25, 2001]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1640 Protein-bound iodine test system. ( a ) *Identification.* A protein-bound iodine test system is a device intended to measure protein-bound iodine in serum. Measurements of protein-bound iodine obtained by this device are used in the diagnosis and treatment of thyroid disorders.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 53 FR 21449, June 8, 1988; 66 FR 38788, July 25, 2001]
§ 515.26 Services of notices and orders. All notices and orders under this part 515 and section 512 of the Federal Food, Drug, and Cosmetic Act (the act) pertaining to medicated feed mill licenses shall be served: ( a ) In person by any officer or employee of the Department of Health and Human Services designated by the Commissioner of Food and Drugs; or
( b ) By mailing the order by certified mail addressed to the applicant or respondent at the applicant or respondent's last known address in the records of the Food and Drug Administration.
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.3605 Pacing system analyzer. ( a ) *Identification.* A pacing system analyzer (PSA) is a prescription device that combines the functionality of a pacemaker electrode function tester (§ 870.3720) and an external pacemaker pulse generator (EPPG) (§ 870.3600). It is connected to a pacemaker lead and uses a power supply and electronic circuits to supply an accurately calibrated, variable pacing pulse for measuring the patient's pacing threshold and intracardiac R-wave potential. A PSA may be a single, dual, or triple chamber system and can simultaneously deliver pacing therapy while testing one or more implanted pacing leads.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Appropriate analysis/testing must validate electromagnetic compatibility (EMC) within a hospital environment.
( 2 ) Electrical bench testing must demonstrate device safety during intended use. This must include testing with the specific power source (*i.e.,* battery power, AC mains connections, or both).
( 3 ) Non-clinical performance testing data must demonstrate the performance characteristics of the device. Testing must include the following: ( i ) Testing must demonstrate the accuracy of monitoring functions, alarms, measurement features, therapeutic features, and all adjustable or programmable parameters as identified in labeling;
( ii ) Mechanical bench testing of material strength must demonstrate that the device and connection cables will withstand forces or conditions encountered during use;
( iii ) Simulated use analysis/testing must demonstrate adequate user interface for adjustable parameters, performance of alarms, display screens, interface with external devices (*e.g.* data storage, printing), and indicator(s) functionality under intended use conditions; and
( iv ) Methods and instructions for cleaning the pulse generator and connection cables must be validated.
( 4 ) Appropriate software verification, validation, and hazard analysis must be performed.
( 5 ) Labeling must include the following: ( i ) The labeling must clearly state that these devices are intended for use in a hospital environment and under the supervision of a clinician trained in their use;
( ii ) Connector terminals should be clearly, unambiguously marked on the outside of the PSA. The markings should identify positive (+) and negative (−) polarities. Dual chamber devices should clearly identify atrial and ventricular terminals. Triple chamber devices should clearly identify atrial, right ventricular, and left ventricular terminals;
( iii ) The labeling must list all pacing modes available in the device;
( iv ) Labeling must include a detailed description of any special capabilities (*e.g.,* overdrive pacing or automatic mode switching);
( v ) Labeling must limit the use of external pacing to the implant procedure; and
( vi ) Appropriate electromagnetic compatibility information must be included.
[81 FR 22350, Apr. 18, 2016]